Skip to main content

Advertisement

SpringerLink
Log in

Management Issues and Controversies in Low-Risk Patients with Essential Thrombocythemia and Polycythemia Vera

  • Myeloproliferative Neoplasms (BL Stein, Section Editor)
  • Published:
Current Hematologic Malignancy Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Essential thrombocythemia (ET) and polycythemia vera (PV) are the most common myeloproliferative neoplasms (MPNs). Treatment of ET and PV is based on the risk for subsequent thrombosis. High-risk patients, defined as older than 60, JAK2 V617F–positive patients, or patients with a history of prior thrombosis, merit cytoreduction to control blood counts, whereas a watchful waiting paradigm is utilized in low-risk patients. However, low-risk patients have a host of other specific management issues that arise during their disease course. This review will discuss the most common management issues specific to the care of low-risk patients, including anti-platelet therapy dosing, pregnancy, and indications for early cytoreduction.

Recent Findings

Although low-dose aspirin is well established in PV, its indications and dosing regimens are less clear in ET. Recent evidence has supported twice daily low-dose aspirin in ET and observation alone in very low–risk ET patients. Pregnancy is not contraindicated in MPNs, and we recommend aspirin throughout pregnancy with consideration for prophylactic postpartum anticoagulation. High phlebotomy needs, symptom burden, and extreme thrombocytosis are common reasons for initiation of cytoreduction in low-risk patients, although we typically do not start cytoreduction for an isolated high platelet count alone. Recent data has also demonstrated a potential disease-modifying effect of interferons in MPNs, with some experts now advocating the early use of interferon in low-risk patients, although more mature data is needed before practice guidelines change.

Summary

We evaluate the literature to inform clinical decision-making regarding these controversies, including most recent data that has challenged the “watchful waiting” paradigm. Our discussion provides guidance on common clinical scenarios seen in low-risk ET and PV patients, who face a myriad of complex management decisions in their care.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Tefferi A, Elliott M. Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F. Semin Thromb Hemost. 2007;33(4):313–20.

    Article  PubMed  CAS  Google Scholar 

  2. Barbui T, Vannucchi AM, Buxhofer-Ausch V, et al. Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia. Blood Cancer J. 2015;5:e369.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  3. Marchioli R, Finazzi G, Landolfi R, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol. 2005;23(10):2224–32.

    Article  PubMed  Google Scholar 

  4. Network NCC. Myeloproliferative neoplasms (version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mpn_blocks.pdf. Accessed August 17, 2019.

  5. Cortelazzo S, Finazzi G, Ruggeri M, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med. 1995;332(17):1132–7.

    Article  PubMed  CAS  Google Scholar 

  6. Kaplan ME, Mack K, Goldberg JD, Donovan PB, Berk PD, Wasserman LR. Long-term management of polycythemia vera with hydroxyurea: a progress report. Semin Hematol. 1986;23(3):167–71.

    PubMed  CAS  Google Scholar 

  7. Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004;350(2):114–24.

    Article  PubMed  CAS  Google Scholar 

  8. Chu DK, Hillis CM, Leong DP, Anand SS, Siegal DM. Benefits and risks of antithrombotic therapy in essential thrombocythemia: a systematic review. Ann Intern Med. 2017;167(3):170–80.

    Article  PubMed  Google Scholar 

  9. Alvarez-Larran A, Cervantes F, Pereira A, et al. Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia. Blood. 2010;116(8):1205–10 (quiz 387).

  10. Alvarez-Larran A, Pereira A, Guglielmelli P, et al. Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation. Haematologica. 2016;101(8):926–31.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  11. Dragani A, Pascale S, Recchiuti A, et al. The contribution of cyclooxygenase-1 and -2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythemia: implications for antiplatelet therapy. Blood. 2010;115(5):1054–61.

    Article  PubMed  CAS  Google Scholar 

  12. Rocca B, Ciabattoni G, Tartaglione R, et al. Increased thromboxane biosynthesis in essential thrombocythemia. Thromb Haemost. 1995;74(5):1225–30.

    Article  PubMed  CAS  Google Scholar 

  13. Viallard JF, Solanilla A, Gauthier B, et al. Increased soluble and platelet-associated CD40 ligand in essential thrombocythemia and reactive thrombocytosis. Blood. 2002;99(7):2612–4.

    Article  PubMed  CAS  Google Scholar 

  14. Pascale S, Petrucci G, Dragani A, et al. Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target. Blood. 2012;119(15):3595–603.

    Article  PubMed  CAS  Google Scholar 

  15. De Stefano V, Rocca B, Tosetto A, et al. The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: implementation of the serum thromboxane B2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting. Blood Cancer J. 2018;8(6):49.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Rocca B, Tosetto A, Betti S, et al. A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia. Blood. 2020;136(2):171–82. The randomized ARES trial evaluates three dosing regimens of aspirin in ET patients, and found that twice daily and three-times daily aspirin results in greater platelet inhibition of COX1 compared to once daily dosing. Twice daily regimens are better tolerated than three-times daily, with no differences in pharmacologic inhibition. This trial provides early evidence for alternative dosing mechanisms of aspirin in ET, which is an essential component of ET management. 

  17. Tefferi A, Vannucchi AM, Barbui T. Essential thrombocythemia treatment algorithm 2018. Blood Cancer J. 2018;8(1):2.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Tefferi A, Vaidya R, Caramazza D, Finke C, Lasho T, Pardanani A. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol. 2011;29(10):1356–63.

    Article  PubMed  CAS  Google Scholar 

  19. Pourcelot E, Trocme C, Mondet J, Bailly S, Toussaint B, Mossuz P. Cytokine profiles in polycythemia vera and essential thrombocythemia patients: clinical implications. Exp Hematol. 2014;42(5):360–8.

    Article  PubMed  CAS  Google Scholar 

  20. Bower JE, Ganz PA, Aziz N, Fahey JL. Fatigue and proinflammatory cytokine activity in breast cancer survivors. Psychosom Med. 2002;64(4):604–11.

    Article  PubMed  Google Scholar 

  21. Mesa RA, Schwager S, Radia D, et al. The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Leuk Res. 2009;33(9):1199–203.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Scherber R, Dueck AC, Johansson P, et al. The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood. 2011;118(2):401–8.

    Article  PubMed  CAS  Google Scholar 

  23. Emanuel RM, Dueck AC, Geyer HL, et al. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol. 2012;30(33):4098–103.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Barosi G, Mesa R, Finazzi G, et al. Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. Blood. 2013;121(23):4778–81.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  25. Mesa R, Miller CB, Thyne M, et al. Myeloproliferative neoplasms (MPNs) have a significant impact on patients’ overall health and productivity: the MPN Landmark survey. BMC Cancer. 2016;16:167.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  26. Geyer HL, Scherber RM, Dueck AC, et al. Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients. Blood. 2014;123(24):3803–10. This study provides granular analysis of symptom burden profilers in MPN patients. Symptoms can be clustered into distinct groups, which do not not necessarily correspond to risk stratification. Distinct symptom clusters indicate possible biologic subgroups within MPNs, and underscore the importance of routine symptom monitoring in the care of MPN patients. 

  27. Vannucchi AM, Kiladjian JJ, Griesshammer M, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015;372(5):426–35.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  28. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799–807.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  29. Harrison CN, Mead AJ, Panchal A, et al. Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide. Blood. 2017;130(17):1889–97.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  30. Marchioli R, Finazzi G, Specchia G, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013;368(1):22–33.

    Article  PubMed  CAS  Google Scholar 

  31. De Domenico I, Lo E, Ward DM, Kaplan J. Hepcidin-induced internalization of ferroportin requires binding and cooperative interaction with Jak2. Proc Natl Acad Sci U S A. 2009;106(10):3800–5.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Pratt JJ, Khan KS. Non-anaemic iron deficiency - a disease looking for recognition of diagnosis: a systematic review. Eur J Haematol. 2016;96(6):618–28.

    Article  PubMed  CAS  Google Scholar 

  33. Scherber RM, Geyer HL, Dueck AC, et al. The potential role of hematocrit control on symptom burden among polycythemia vera patients: insights from the CYTO-PV and MPN-SAF patient cohorts. Leuk Lymphoma. 2017;58(6):1481–7.

    Article  PubMed  CAS  Google Scholar 

  34. Silver RT, Gjoni S. The hematocrit value in polycythemia vera: caveat utilitor. Leuk Lymphoma. 2015;56(5):1540–1.

    Article  PubMed  Google Scholar 

  35. Verstovsek S, Harrison CN, Kiladjian JJ, et al. Markers of iron deficiency in patients with polycythemia vera receiving ruxolitinib or best available therapy. Leuk Res. 2017;56:52–9.

    Article  PubMed  CAS  Google Scholar 

  36. Ginzburg YZ, Feola M, Zimran E, Varkonyi J, Ganz T, Hoffman R. Dysregulated iron metabolism in polycythemia vera: etiology and consequences. Leukemia. 2018;32(10):2105–16.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  37. Kremyanskaya M, Ginzburg Y, Kuykendall AT, et al. PTG-300 Eliminates the need for therapeutic phlebotomy in both low and high-risk polycythemia vera patients. Blood. 2020;136(Supplement 1):33–5.

    Article  Google Scholar 

  38. Srour SA, Devesa SS, Morton LM, et al. Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms in the United States, 2001–12. Br J Haematol. 2016;174(3):382–96.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  39. Alimam S, Bewley S, Chappell LC, et al. Pregnancy outcomes in myeloproliferative neoplasms: UK prospective cohort study. Br J Haematol. 2016;175(1):31–6.

    Article  PubMed  Google Scholar 

  40. • Maze D, Kazi S, Gupta V, et al. Association of treatments for myeloproliferative neoplasms during pregnancy with birth rates and maternal outcomes: a systematic review and meta-analysis. JAMA Netw Open. 2019;2(10):e1912666. This systematic review and meta-analysis synthesizes recent findings in the literature on the outcomes of pregnant women with MPNs. Pregnancy outcomes are overall excellent with high birth rates. Aspirin and interferon use are associated with improved live birth rates. 

  41. Griesshammer M, Sadjadian P, Wille K. Contemporary management of patients with BCR-ABL1-negative myeloproliferative neoplasms during pregnancy. Expert Rev Hematol. 2018;11(9):697–706.

    Article  PubMed  CAS  Google Scholar 

  42. How J, Leiva O, Bogue T, et al. Pregnancy outcomes, risk factors, and cell count trends in pregnant women with essential thrombocythemia. Leuk Res. 2020;98:106459.

    Article  PubMed  CAS  Google Scholar 

  43. Passamonti F, Randi ML, Rumi E, et al. Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation. Blood. 2007;110(2):485–9.

    Article  PubMed  CAS  Google Scholar 

  44. Rumi E, Bertozzi I, Casetti IC, et al. Impact of mutational status on pregnancy outcome in patients with essential thrombocytemia. Haematologica. 2015;100(11):e443–5.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  45. Melillo L, Tieghi A, Candoni A, et al. Outcome of 122 pregnancies in essential thrombocythemia patients: a report from the Italian registry. Am J Hematol. 2009;84(10):636–40.

    Article  PubMed  Google Scholar 

  46. Gangat N, Wolanskyj AP, Schwager S, Tefferi A. Predictors of pregnancy outcome in essential thrombocythemia: a single institution study of 63 pregnancies. Eur J Haematol. 2009;82(5):350–3.

    Article  PubMed  Google Scholar 

  47. Skeith L, Carrier M, Robinson SE, Alimam S, Rodger MA. Risk of venous thromboembolism in pregnant women with essential thrombocythemia: a systematic review and meta-analysis. Blood. 2017;129(8):934–9.

    Article  PubMed  CAS  Google Scholar 

  48. Beauverd Y, Radia D, Cargo C, et al. Pegylated interferon alpha-2a for essential thrombocythemia during pregnancy: outcome and safety. A case series. Haematologica. 2016;101(5):e182–4.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  49. How C-J, Leiva O, Bogue T, et al. Pregnancy outcomes, risk factors, and gestational cell count trends in pregnant women with essential thrombocythemia and polycythemia vera. Blood. 2019;134(Supplement_1):4172.

    Article  Google Scholar 

  50. Sanchez-Aguilera A, Arranz L, Martin-Perez D, et al. Estrogen signaling selectively induces apoptosis of hematopoietic progenitors and myeloid neoplasms without harming steady-state hematopoiesis. Cell Stem Cell. 2014;15(6):791–804.

    Article  PubMed  CAS  Google Scholar 

  51. Turhan AG, Humphries RK, Cashman JD, Cuthbert DA, Eaves CJ, Eaves AC. Transient suppression of clonal hemopoiesis associated with pregnancy in a patient with a myeloproliferative disorder. J Clin Invest. 1988;81(6):1999–2003.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  52. Harrison C, Baxter J, Boucher RH, et al. Effects of tamoxifen on the mutant allele burden and disease course in patients with myeloproliferative neoplasms - results of the TAMARIN study. Blood. 2020;136(Supplement 1):33–5.

    Article  Google Scholar 

  53. Szuber N, Vallapureddy RR, Penna D, et al. Myeloproliferative neoplasms in the young: Mayo Clinic experience with 361 patients age 40 years or younger. Am J Hematol. 2018;93(12):1474–84.

    Article  PubMed  CAS  Google Scholar 

  54. Sanchez-Luceros A, Meschengieser SS, Woods AI, et al. Acquired von Willebrand factor abnormalities in myeloproliferative disorders and other hematologic diseases: a retrospective analysis by a single institution. Haematologica. 2002;87(3):264–70.

    PubMed  CAS  Google Scholar 

  55. Lancellotti S, Dragani A, Ranalli P, et al. Qualitative and quantitative modifications of von Willebrand factor in patients with essential thrombocythemia and controlled platelet count. J Thromb Haemost. 2015;13(7):1226–37.

    Article  PubMed  CAS  Google Scholar 

  56. Rottenstreich A, Kleinstern G, Krichevsky S, Varon D, Lavie D, Kalish Y. Factors related to the development of acquired von Willebrand syndrome in patients with essential thrombocythemia and polycythemia vera. Eur J Intern Med. 2017;41:49–54.

    Article  PubMed  CAS  Google Scholar 

  57. Mital A, Prejzner W, Bieniaszewska M, Hellmann A. Prevalence of acquired von Willebrand syndrome during essential thrombocythemia: a retrospective analysis of 170 consecutive patients. Pol Arch Med Wewn. 2015;125(12):914–20.

    PubMed  Google Scholar 

  58. Campbell PJ, MacLean C, Beer PA, et al. Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort. Blood. 2012;120(7):1409–11.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  59. Finazzi G, Carobbio A, Thiele J, et al. Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria. Leukemia. 2012;26(4):716–9.

    Article  PubMed  CAS  Google Scholar 

  60. Tefferi A, Gangat N, Wolanskyj AP. Management of extreme thrombocytosis in otherwise low-risk essential thrombocythemia; does number matter? Blood. 2006;108(7):2493–4.

    Article  PubMed  CAS  Google Scholar 

  61. Tefferi A, Szuber N, Pardanani A, Hanson CA, Vannucchi AM, Barbui T, Gangat N. Extreme thrombocytosis in low-risk essential thrombocythemia: retrospective review of vascular events and treatment strategies. Am J Hematol. 2021;96(6):E182–4. https://doi.org/10.1002/ajh.26137.

  62. Gangat N, Szuber N, Jawaid T, Hanson CA, Pardanani A, Tefferi A. Young platelet millionaires with essential thrombocythemia. Am J Hematol. 2021;96(4):E93–5.

    Article  PubMed  Google Scholar 

  63. Palandri F, Polverelli N, Catani L, et al. Bleeding in essential thrombocythaemia: a retrospective analysis on 565 patients. Br J Haematol. 2012;156(2):281–4.

    Article  PubMed  CAS  Google Scholar 

  64. Galvez C, Stein BL. Thrombocytosis and thrombosis: is there really a correlation? Curr Hematol Malig Rep. 2020;15(4):261–7.

    Article  PubMed  Google Scholar 

  65. Gangat N, Wolanskyj AP, McClure RF, et al. Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients. Leukemia. 2007;21(2):270–6.

    Article  PubMed  CAS  Google Scholar 

  66. Gisslinger H, Klade C, Georgiev P, et al. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study. Lancet Haematol. 2020;7(3):e196–208.

    Article  PubMed  Google Scholar 

  67. Mascarenhas JO, Prchal JT, Rambaldi A, et al. Interim analysis of the Myeloproliferative Disorders Research Consortium MPD-RC 112 global phase iii trial of front line pegylated interferon alpha-2a vs. hydroxyurea in high risk polycythemia vera and essential thrombocythemia. Blood. 2016;128(22):479.

    Article  Google Scholar 

  68. Yacoub A, Mascarenhas J, Mesa RA, et al. Final results of prospective treatment with pegylated interferon alfa-2a for patients with polycythemia vera and essential thrombocythemia in first and second-line settings. Blood. 2019;1341(Supplement_1):2943.

    Article  Google Scholar 

  69. How J, Hobbs G. Use of interferon alfa in the treatment of myeloproliferative neoplasms: perspectives and review of the literature. Cancers (Basel). 2020;12(7):1954. https://doi.org/10.3390/cancers12071954.

  70. Daltro De Oliveira R, Soret-Dulphy J, Zhao L-P, et al. Interferon-alpha (IFN) therapy discontinuation is feasible in myeloproliferative neoplasm (MPN) patients with complete hematological remission. Blood. 2020;136(Supplement 1):35–6.

    Article  Google Scholar 

  71. • Abu-Zeinah G, Krichevsky S, Cruz T, Hoberman G, Jaber D, Savage N, Sosner C, Ritchie EK, Scandura JM, Silver RT. Interferon-alpha for treating polycythemia vera yields improved myelofibrosis-free and overall survival. Leukemia. 2021. https://doi.org/10.1038/s41375-021-01183-8. This retrospective study finds improved myelofibrosis-free and overall survival in PV patients treated with interferon-alpha compared to hydroxyurea or phlebotomy alone. Although prospective studies are necessary to validate these results, this study provides evidence challenging the current “watchful waiting” paradigm in low-risk PV patients.

  72. • Barbui T, Vannucchi AM, De Stefano V, et al. Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial. Lancet Haematol. 2021;8(3):e175–e184. https://doi.org/10.1016/S2352-3026(20)30373-2. This randomized phase 2 trial found a significant benefit with regard to hematocrit control in low-risk PV patients treated with interferon compared to phlebotomy alone. Treatment was well tolerated. This study provides rationale for early use of cytoreduction with interferon in low-risk PV patients.

  73. Scherber RM, Kosiorek HE, Senyak Z, et al. Comprehensively understanding fatigue in patients with myeloproliferative neoplasms. Cancer. 2016;122(3):477–85.

    Article  PubMed  Google Scholar 

  74. Pedersen KM, Zangger G, Brochmann N, et al. The effectiveness of exercise-based rehabilitation to patients with myeloproliferative neoplasms-an explorative study. Eur J Cancer Care (Engl). 2018;27(5):e12865.

    Article  Google Scholar 

  75. Gowin K, Langlais BT, Kosiorek HE, et al. The SIMM study: survey of integrative medicine in myeloproliferative neoplasms. Cancer Med. 2020;9(24):9445–53.

    Article  PubMed  PubMed Central  Google Scholar 

  76. Huberty J, Eckert R, Dueck A, et al. Online yoga in myeloproliferative neoplasm patients: results of a randomized pilot trial to inform future research. BMC Complement Altern Med. 2019;19(1):121.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  77. Mesa RA, Niblack J, Wadleigh M, et al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. Cancer. 2007;109(1):68–76.

    Article  PubMed  Google Scholar 

  78. Diehn F, Tefferi A. Pruritus in polycythaemia vera: prevalence, laboratory correlates and management. Br J Haematol. 2001;115(3):619–21.

    Article  PubMed  CAS  Google Scholar 

  79. Baldo A, Sammarco E, Plaitano R, Martinelli V, Monfrecola A. Narrowband (TL-01) ultraviolet B phototherapy for pruritus in polycythaemia vera. Br J Dermatol. 2002;147(5):979–81.

    Article  PubMed  CAS  Google Scholar 

  80. Frewin R, Dowson A. Headache in essential thrombocythaemia. Int J Clin Pract. 2012;66(10):976–83.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Massachusetts General Hospital, Harvard Medical School, Zero Emerson, Office 138, Boston, MA, 02114, USA

    Joan How & Gabriela Hobbs

  2. Division of Hematology, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, 02115, USA

    Joan How

  3. Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 02115, USA

    Joan How

Authors
  1. Joan How
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gabriela Hobbs
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gabriela Hobbs.

Ethics declarations

Conflict of Interest

The authors declare no competing interests.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Myeloproliferative Neoplasms

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

How, J., Hobbs, G. Management Issues and Controversies in Low-Risk Patients with Essential Thrombocythemia and Polycythemia Vera. Curr Hematol Malig Rep 16, 473–482 (2021). https://doi.org/10.1007/s11899-021-00649-x

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11899-021-00649-x

Keywords

Search

Navigation